Previous 10 | Next 10 |
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence . The pharmaceutical company closed out October at $6.94 and opened November at $7. It rose to a 52-week high of $9.85 on Nov. 25 and closed out the month at $9.04. Its s...
Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Ad...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Zigres / Shutterstock.com Tesla (NASDAQ: TSLA ) stock is in the news Friday as investors react to the electric vehicle company (EV) recalling 30,000 Model X units . The recall of these EVs has to do w...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Tinseltown / Shutterstock Ticketmaster, which is owned by Live Nation Entertainment (NYSE: LYV ), is caught up in drama after it had to cancel sales of Taylor Swift tickets. The controversy started on...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s a good-news, bad-news situation happening with Provention Bio (NASDAQ: PRVB ) today. Provention’s management is celebrating a watershed moment with a Food and Drug Administration (FDA) approval of ...
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D PR Newswire TZIELD is the first disease-modifying ther...
Provention Bio, Inc. (PRVB) Q3 2022 Results Conference Call November 03, 2022 08:00 AM ET Company Participants Heidy King-Jones - Chief Legal Officer Ashleigh Palmer - CEO and Co-Founder Jason Hoitt - Chief Commercial Officer Thierry Chauche - CFO Confe...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It may be a mixed session for the overall market on Thursday, but not for Provention Biosciences (NASDAQ: PRVB ). That’s as PRVB stock is up 25% so far in the session and hitting its highest level since July 20...
Provention Bio, Inc. ( NASDAQ: PRVB ) added ~27% intraday Thursday after the clinical-stage biopharma announced with its Q3 2022 results that the FDA issued its proposed labeling for the experimental diabetes therapy teplizumab. An anti-CD3 monoclonal antibody, tep...
Provention Bio press release ( NASDAQ: PRVB ): Q3 GAAP EPS of -$0.34 beats by $0.08 . Revenue of $0.8M (+17.6% Y/Y) beats by $0.02M . Cash-based operating expenses for the third quarter of 2022 were $26.4M, which exclude non-cash, stock-based compensation expen...
News, Short Squeeze, Breakout and More Instantly...
Provention Bio, Inc. (NASDAQ: PRVB) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 3.14% on the day to $24.99. Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and comme...
2023-04-06 11:29:16 ET What Are Penny Stocks? The market for penny stocks has continued growing over the last few years. But what are these stocks in the first place? The general definition of penny stocks includes shares of companies trading below $5. Making money with penny st...
NEW YORK, NY / ACCESSWIRE / March 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Seagen Inc. (NASDAQ:SGEN)'s sale t...